THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES. THE OFFER AND SALE OF THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT ) OR UNDER THE APPLICABLE SECURITIES LAWS OF ANY OTHER STATE OR JURISDICTION OF THE UNITED STATES, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT) ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM REGISTRATION UNDER THE US SECURITIES ACT AND IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES. ADDITIONALLY, THE OFFER AND SALE OF THE SECURITIES REFERRED TO HEREIN HAS NOT BEEN AND WILL NOT BE REGISTERED UNDER THE APPLICABLE SECURITIES LAWS OF AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA AND, SUBJECT TO CERTAIN EXCEPTIONS, THE SECURITIE
Tremendous success for MedinCell s €30 million capital increase for qualified investors
Strong support from French and international leading shareholders and investors
Regulatory News:
MedinCell (Paris:MEDCL)
(FR0004065605 MEDCL), a clinical stage pharmaceutical company developing a portfolio of long-acting injectable products in various therapeutic areas (the
Company ), is today announcing the successful completion of its €29.8 million capital increase via a placement with French and international qualified investors through an accelerated bookbuilding process (the
Offering
1 and ODDO BHF SCA are acting as Joint Global Coordinators and Joint Bookrunners.
Buoyed by very strong interest during the book building process, the capital increase was priced at a modest discount of 8% to the closing price of the Company s shares on the Euronext Paris regulated market on February 10, 2021 and accounted for 10,9% of the Company s share capital through the issuance of 2.414.2
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
SECO to IPO
SECO, the embedded specialist, is to IPO on the Mercato Telematico Azionario managed by Borsa Italiana (“MTA”) as part of the market’s Star Segment.
“By going public, we aim to raise the financial resources to further accelerate our growth and reinforce our international presence,” says CEO Massimo Mauri (pictured), “over the course of 2020 we worked on the evolution of our business model and, thanks in part to the acquisitions of Ispirata and Hopenly and their integration – finalized with the creation of SECO Mind – we have become a strategic partner in businesses’ IoT-based digital transformation and have laid solid foundations for future development.”
MedinCell Announces a Capital Increase of a c.€30 Million
Portefeuille au 31 janvier 2021 (Graphic: Business Wire)
This press release is not intended for publication or distribution in the United States, Canada, Japan or Australia.
MedinCell (FR0004065605 MEDCL) (Paris:MEDCL), a clinical stage pharmaceutical company developing a portfolio of long-acting injectable products in various therapeutic areas (the
Company ), announces today a capital increase of €c.30 million through an offering to qualified investors, both French and international, by way of an accelerated bookbuilding process (the
Offering
Reasons for the Offering We have been in the spotlight recently because of the very successful Phase 3 trial of the first product based on our BEPO